Deoxyshikonin reversibly inhibits cytochrome P450 2B6
© 2020 John Wiley & Sons, Ltd..
Deoxyshikonin, a natural shikonin derivative, is the major component of Lithospermum erythrorhizon and exhibits various pharmacological effects such as lymphangiogenetic, antibacterial, wound healing, and anticancer effects. To investigate the herb-drug interaction potential associated with deoxyshikonin, the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes were examined using cocktail substrate-incubated human liver microsomes. Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 μM, and the inhibition was confirmed using purified human CYP2B6. The inhibition was reversible because the inhibitory effect of deoxyshikonin was not dependent on the preincubation time. The results indicated that deoxyshikonin-induced drug-drug interaction should be considered when any herb containing deoxyshikonin is used for conventional medications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Biopharmaceutics & drug disposition - 41(2020), 4-5 vom: 03. Apr., Seite 221-225 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Ju-Hyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
43043-74-9 |
|---|
| Anmerkungen: |
Date Completed 18.03.2021 Date Revised 18.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/bdd.2230 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309478847 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309478847 | ||
| 003 | DE-627 | ||
| 005 | 20231225134013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/bdd.2230 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309478847 | ||
| 035 | |a (NLM)32364297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Ju-Hyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Deoxyshikonin reversibly inhibits cytochrome P450 2B6 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2021 | ||
| 500 | |a Date Revised 18.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons, Ltd. | ||
| 520 | |a Deoxyshikonin, a natural shikonin derivative, is the major component of Lithospermum erythrorhizon and exhibits various pharmacological effects such as lymphangiogenetic, antibacterial, wound healing, and anticancer effects. To investigate the herb-drug interaction potential associated with deoxyshikonin, the inhibitory effects of deoxyshikonin on eight major cytochrome P450 (CYP) enzymes were examined using cocktail substrate-incubated human liver microsomes. Deoxyshikonin strongly inhibited CYP2B6-catalyzed bupropion hydroxylation, with a Ki value of 3.5 μM, and the inhibition was confirmed using purified human CYP2B6. The inhibition was reversible because the inhibitory effect of deoxyshikonin was not dependent on the preincubation time. The results indicated that deoxyshikonin-induced drug-drug interaction should be considered when any herb containing deoxyshikonin is used for conventional medications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cytochrome P450 2B6 | |
| 650 | 4 | |a deoxyshikonin | |
| 650 | 4 | |a herb-drug interaction | |
| 650 | 4 | |a reversible inhibition | |
| 650 | 7 | |a Cytochrome P-450 CYP2B6 Inhibitors |2 NLM | |
| 650 | 7 | |a Naphthoquinones |2 NLM | |
| 650 | 7 | |a deoxyshikonin |2 NLM | |
| 650 | 7 | |a 43043-74-9 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 Enzyme System |2 NLM | |
| 650 | 7 | |a 9035-51-2 |2 NLM | |
| 700 | 1 | |a Choi, Su Min |e verfasserin |4 aut | |
| 700 | 1 | |a Shreatha, Riya |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Gil-Saeng |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Tae Cheon |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sangkyu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biopharmaceutics & drug disposition |d 1994 |g 41(2020), 4-5 vom: 03. Apr., Seite 221-225 |w (DE-627)NLM003938654 |x 1099-081X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2020 |g number:4-5 |g day:03 |g month:04 |g pages:221-225 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/bdd.2230 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2020 |e 4-5 |b 03 |c 04 |h 221-225 | ||